Ryan Specialty Stock Falls Below Insider's $40 Exit Price
Ryan Specialty's Q3 2026 earnings call is set for October 29 at 4:45 p.m. ET, arriving with the stock at $37.67 — below the price at which Co-President and CRO Brendan Mulshine sold $1.62 million in s
Ryan Specialty Stock Falls Below Insider's $40 Exit Price
NEW YORK, October 4 —
Even as Ryan Specialty Holdings, Inc. (RYAN) delivered a 23.3% EPS beat in its most recently reported quarter, the widest margin in four quarters, the stock trades at $37.67, below the $40.51 exit price at which Co-President and CRO Brendan Mulshine sold $1.62 million in shares weeks before the October 29 Q3 call.
- Most recent quarter: $0.74 EPS beat $0.60 consensus by 23.3%, the largest beat in four quarters; prior quarter missed 8.2%.
- CRO Mulshine sold 40,000 shares at $40.51 on September 8 for $1.62 million; the stock now trades at $37.67.
- Short interest at 11.4% of the float; 90-day insider activity: $1.71 million in sales, zero open-market purchases.
Uneven Record, One Outsized Print
The 23.3% beat is Ryan Specialty's strongest quarterly result in four periods: $0.74 actual against a $0.60 consensus. The company is a wholesale broker and managing underwriter that connects specialty insurance carriers with commercial, industrial, and government clients across the U.S., U.K., and Europe. But the surrounding record is uneven: an 8.2% miss three quarters ago and a 0.6% beat four quarters ago bracket the latest result with enough variance to question how much is repeatable. TTM revenue of $3.16 billion growing 7.4% and free cash flow of $585 million look solid, but $3.81 billion in debt against $140 million in cash makes a DCF model sensitive to rate assumptions.
The Selling Pattern
The signal most worth parsing is not the beat but who sold into it. Four days after completing two conversion transactions totaling 80,000 shares, CRO Mulshine sold 40,000 shares at $40.51 on September 8, per Form 4 filings, generating $1.62 million. EVP and CHRO Michael Conklin sold 2,043 shares at $42.26 on August 13 for approximately $86,000. Across the 90-day reporting window, insiders recorded $1.71 million in open-market sales against zero open-market purchases. Mulshine's exit now sits 7.5% above current levels; no insider has yet entered the open market to buy shares at the lower price.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RYAN | $9.7B | 15.6x | -34.8% |
| CNM | $7.6B | 11.8x | -19.9% |
| HAYW | $2.6B | 12.8x | -20.4% |
| EQH | $14.4B | 5.8x | +3.4% |
| STEP | $5.8B | 13.3x | -33.3% |
| GSHD | $1.6B | 16.9x | -31.9% |
October 29 as the Referendum
The October 29 call arrives with analyst consensus of $50.09 implying 33% upside from $37.67, a gap that hinges on whether Q2's beat was a recurring dynamic or a one-period variance. Short interest at 11.4% adds a coiled-spring element: a Q3 beat could force covering, while a miss or cautious guidance would validate the short thesis. Ryan Specialty also filed an 8-K on August 7 disclosing a Material Definitive Agreement, an item worth squaring against the Q3 revenue line. Run the free Ryan Specialty Holdings, Inc. deep-dive ahead of earnings.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Ryan Specialty's Q3 2026 earnings call is set for October 29 at 4:45 p.m. ET, arriving with the stock at $37.67 — below the price at which Co-President and CRO Brendan Mulshine sold $1.62 million in shares just weeks ago. Analysts are targeting $50.09 and the company's most recent quarter beat estimates by 23.3%, yet 11.4% of the float is sold short and insiders have done nothing but sell over the past 90 days.